CONFIDENTIAL TREATMENT REQUESTED ROYALTY PURCHASE AGREEMENT dated as of March 24, 2015 between IMMUNOGEN, INC., HURRICANE, LLC as Seller and IMMUNITY ROYALTY HOLDINGS, L.P. Portions of the exhibit, indicated by the mark “[***],” were omitted and have...Royalty Purchase Agreement • May 8th, 2015 • Immunogen Inc • Pharmaceutical preparations • New York
ROYALTY PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of March 24, 2015 (referred to herein as “the date of this Agreement”), by and among ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), Hurricane, LLC, a Massachusetts limited liability company (the “Seller,” and together with ImmunoGen, the “Selling Parties”) and Immunity Royalty Holdings, L.P., a Delaware limited partnership (the “Purchaser”).
CONFIDENTIAL TREATMENT REQUESTED MULTI-TARGET AGREEMENTMulti-Target Agreement • May 8th, 2015 • Immunogen Inc • Pharmaceutical preparations • New York
This Multi-Target Agreement (this “Agreement”) is made effective as of the date of the last signature below (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, and Millennium Pharmaceuticals, Inc., a Delaware corporation (“Millennium”) and a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, with its principal place of business at 40 Landsdowne Street, Cambridge, Massachusetts 02139. ImmunoGen and Millennium are sometimes each hereinafter referred to individually as a “Party” and collectively as the “Parties.”
